WO2005019200A3 - Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci - Google Patents
Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci Download PDFInfo
- Publication number
- WO2005019200A3 WO2005019200A3 PCT/US2004/026206 US2004026206W WO2005019200A3 WO 2005019200 A3 WO2005019200 A3 WO 2005019200A3 US 2004026206 W US2004026206 W US 2004026206W WO 2005019200 A3 WO2005019200 A3 WO 2005019200A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vla
- integrin antagonists
- piperidine derivatives
- aryl piperidine
- integrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49574003P | 2003-08-14 | 2003-08-14 | |
US60/495,740 | 2003-08-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005019200A2 WO2005019200A2 (fr) | 2005-03-03 |
WO2005019200A3 true WO2005019200A3 (fr) | 2008-01-03 |
Family
ID=34215939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/026206 WO2005019200A2 (fr) | 2003-08-14 | 2004-08-12 | Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005019200A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8946278B2 (en) | 2007-02-07 | 2015-02-03 | Glaxosmithkline Llc | Inhibitors of AkT activity |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20063774B (en) | 1999-06-01 | 2006-03-27 | Biogen Idec Inc | Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders |
DE60236735D1 (de) | 2001-04-13 | 2010-07-29 | Biogen Idec Inc | Antikörper gegen vla-1 |
AU2006229271B2 (en) * | 2005-03-28 | 2012-02-09 | Toyama Chemical Co., Ltd. | Process for production of 1-(3-(2-(1-benzothiophen-5-YL)- ethoxy)propyl)azetidin-3-ol or salts thereof |
JP5388574B2 (ja) * | 2005-05-31 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なヘテロ環式類 |
AU2013204572B2 (en) * | 2006-05-25 | 2015-06-18 | Biogen Ma Inc. | Methods of Treating Stroke |
AU2015227462B2 (en) * | 2006-05-25 | 2017-11-02 | Biogen Ma Inc. | Methods of Treating Stroke |
ES2685802T3 (es) * | 2006-05-25 | 2018-10-11 | Biogen Ma Inc. | Antagonista de VLA-1 para su utilización en el tratamiento de un accidente cerebrovascular |
GB0614947D0 (en) * | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
US20130096160A1 (en) * | 2010-04-14 | 2013-04-18 | Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
JP6345123B2 (ja) | 2012-02-16 | 2018-06-20 | サンタラス, インコーポレイテッド | 抗vla1(cd49a)抗体医薬組成物 |
JPWO2013187462A1 (ja) | 2012-06-14 | 2016-02-08 | 第一三共株式会社 | ピペリジニルピラゾロピリジン誘導体 |
CA2894492A1 (fr) | 2012-12-11 | 2014-06-19 | Takeda Pharmaceuticals Company Limited | Compose heterocyclique |
CA3072362A1 (fr) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | Inhibition de la peptidase 30 specifique de l'ubiquitine |
AU2019356011A1 (en) | 2018-10-05 | 2021-04-01 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6291453B1 (en) * | 1997-07-31 | 2001-09-18 | Athena Neurosciences, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US20020019419A1 (en) * | 2000-06-22 | 2002-02-14 | De Laszlo Stephen E. | Substituted isonipecotyl derivatives as inhibitors of cell adhesion |
US6486154B1 (en) * | 1997-07-29 | 2002-11-26 | Zeneca Limited | (Hetero) aryl-sulfonamide derivatives, their preparation and their use as factor XA inhibitors |
-
2004
- 2004-08-12 WO PCT/US2004/026206 patent/WO2005019200A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486154B1 (en) * | 1997-07-29 | 2002-11-26 | Zeneca Limited | (Hetero) aryl-sulfonamide derivatives, their preparation and their use as factor XA inhibitors |
US6291453B1 (en) * | 1997-07-31 | 2001-09-18 | Athena Neurosciences, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US20020019419A1 (en) * | 2000-06-22 | 2002-02-14 | De Laszlo Stephen E. | Substituted isonipecotyl derivatives as inhibitors of cell adhesion |
Non-Patent Citations (2)
Title |
---|
C. E. GUTTERIDGE ET. AL.: "N-(3-Phenylsulfonyl-3-piperidonyl)-phenylalanine Derivatives as Potent, Selective, VLA-4 Antagonists.", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 5, 10 March 2003 (2003-03-10), pages 885 - 890, XP001179737 * |
K. SAGI ET. AL: "Rational Design, Synthesis and Strucutre-Activity Relationships of Novel Factor Xa Inhibitors. 2-(Substituted-4-amidinophenyl)-pyruvic and propionic Acids", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 18, 8 May 2003 (2003-05-08), pages 1845 - 1857, XP002319434 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8946278B2 (en) | 2007-02-07 | 2015-02-03 | Glaxosmithkline Llc | Inhibitors of AkT activity |
Also Published As
Publication number | Publication date |
---|---|
WO2005019200A2 (fr) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005016883A3 (fr) | Derives d'acrylamide servant d'antagonistes de l'integrine vla-1, et leurs utilisations | |
WO2004098494A3 (fr) | Composés, compositions et procédés | |
WO2006126081A3 (fr) | Pyridine [2,3-b] pyrazinones | |
WO2008064351A3 (fr) | (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8 | |
WO2006044362A3 (fr) | Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide | |
WO2006034039A3 (fr) | Morphinanes substitues et leurs procedes d'utilisation | |
WO2006085149A3 (fr) | Methodes et compositions de traitement de maladies liees a l'amyloide | |
WO2005019200A3 (fr) | Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci | |
WO2004078116A3 (fr) | Inhibiteurs de la p 38 et leurs procedes d'utilisation | |
WO2004006858A3 (fr) | Composes, compositions et methodes d'utilisation de ces derniers | |
IL216579A0 (en) | Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same | |
WO2004011611A3 (fr) | Anticorps anti-taci et utilisations de ceux-ci | |
WO2005110994A3 (fr) | Derives de pyrazolyl uree substitues utiles dans le traitement du cancer | |
WO2004014322A3 (fr) | Compositions immunomodulatrices, leurs methodes de preparation et utilisation | |
FR2841900B1 (fr) | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations | |
WO2002096361A3 (fr) | Derives de 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone utilises comme inhibiteurs de kinase | |
WO2004009062A3 (fr) | Antagonistes du recepteur nmda et leur utilisation pour inhiber l'hyperphosphorylation de la proteine associee aux microtubules tau | |
WO2004113277A3 (fr) | Procedes et compositions de traitement de maladies associees aux amyloides | |
WO2005086656A3 (fr) | Derives d'heteroarylaminopyrazole utilises pour traiter le diabete | |
WO2003059903A3 (fr) | Derives substitues de 4-aminopyridine | |
WO2005030188A3 (fr) | Derives de phenyl-piperazine en tant que modulateurs des recepteurs muscariniques | |
WO2007109279A3 (fr) | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation | |
WO2007016352A3 (fr) | Compositions orales liquides de losartan | |
MX2007006387A (es) | Derivados de piridina 3-substituidos como antagonistas h3. | |
IL191751A0 (en) | Pyrrolo[2,3-c]pyridine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |